&nbsp;

H-CDM_FITInstructions

New

Mar 2026

Document

H-CDM_FITInstructions-FR

New

Mar 2026

Document

H-KOH_FITInstructions

New

Mar 2026

Document

H-KOH_FITInstructions-FR

New

Mar 2026

Document

H-FIT_PrimaryCareProviderFAQs

New

Mar 2026

Regimen

ENHE

Cancer Type:

Breast

Intent: Palliative

Funding:

New Drug Funding Program

Trastuzumab Deruxtecan - Unresectable Locally Advanced or Metastatic Breast Cancer

New Drug Funding Program

Trastuzumab Deruxtecan - HER2-low Unresectable Locally Advanced or Metastatic Breast Cancer

Enhertu trastuzumab deruxtecan

Drugs Used:

Quick Link(s):

Regimen Monograph

Mar 2026

Regimen

ENFO+PEMB

Cancer Type:

Genitourinary,

Bladder / Urothelial

Intent: Neoadjuvant, Adjuvant

Drugs Used:

enfortumab vedotin (Unfunded),

pembrolizumab (Unfunded)

Quick Link(s):

Regimen Monograph

New

Apr 2026

High Risk Ontario Breast Screening Program Locations List

Drug

encorafenib

Other Name(s): Braftovi®

Quick Link(s):

Drug Monograph, Patient Info Sheet

Updated

Apr 2026

Regimen

ENCO+CETU

Cancer Type:

Gastrointestinal,

Colorectal,

Small bowel and appendix

Intent: Palliative

Funding:

Exceptional Access Program

encorafenib - In combination with cetuximab or panitumumab in previously treated BRAF V600E-mutated metastatic colorectal cancer, based on criteria

New Drug Funding Program

Cetuximab - In Combination with Encorafenib for Previously Treated Metastatic Colorectal Cancer

Drugs Used:

encorafenib,

cetuximab

Quick Link(s):

Regimen Monograph

Updated

Apr 2026

Regimen

ENCO+PNTM

Cancer Type:

Gastrointestinal,

Colorectal,

Small bowel and appendix

Intent: Palliative

Funding:

Exceptional Access Program

encorafenib - In combination with cetuximab or panitumumab in previously treated BRAF V600E-mutated metastatic colorectal cancer, based on criteria

New Drug Funding Program

Panitumumab - In Combination with Encorafenib for Previously Treated Metastatic Colorectal Cancer

Drugs Used:

encorafenib,

PANitumumab